"Jodi Arias: Behind the Headlines," at 10, recaps the trial.
In this randomized, double-blind, placebo-controlled phase I clinical trial, single and multiple ascending intravenous doses recAP were well tolerated and could be administered without any safety concerns [62].
Amelia McDonell-Parry, a journalist covering the trial for The Frisky, accompanied her exhaustive recaps with unflattering sketches of Vignarajah and state's witnesses.
We conducted a phase I clinical trial to evaluate tolerability, safety and pharmacokinetics of recAP in healthy volunteers.
A recap of key dates in the Amanda Knox trial on HuffPost World.
When it ended, I changed channels and happened upon a local news recap of the day's events at the criminal trial of Rod Blagojevich.
Not that anyone should have expected Roger Clemens's trial to elevate the discourse on sports doping, but a line in the Associated Press recap of yesterday's opening statements compels some gnashing of teeth.
Subsequently, the efficacy of recAP is currently being investigated in an adaptive, multicenter, phase II clinical trial in patients with sepsis-associated AKI (NTC02182440).
In a randomized, double-blind, placebo-controlled phase I trial, healthy volunteers received via a 1-hour i.v. infusion a single dose of recAP (200, 500, 1,000 or 2,000 U/kg; n = 33) or multiple doses of recAP (500 or 1,000 U/kg; n = 18) on three consecutive days (n = 18).
These results pave the way to investigate the potential of recAP as a new treatment option for sepsis-associated AKI in a phase II clinical trial, which will start at the end of 2014 [Clinical Trial Register:NCT02182440].
